{"id":"https://openalex.org/W3098266159","doi":"https://doi.org/10.1016/j.ijid.2020.11.142","title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial","display_name":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial","publication_year":2020,"publication_date":"2020-11-16","ids":{"openalex":"https://openalex.org/W3098266159","doi":"https://doi.org/10.1016/j.ijid.2020.11.142","mag":"3098266159","pmid":"https://pubmed.ncbi.nlm.nih.gov/33212256","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7668212"},"language":"en","primary_location":{"id":"doi:10.1016/j.ijid.2020.11.142","doi":"https://doi.org/10.1016/j.ijid.2020.11.142","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ijid.2020.11.142","pdf_url":"http://www.ijidonline.com/article/S120197122032453X/pdf","source":{"id":"https://openalex.org/S35071406","display_name":"International Journal of Infectious Diseases","issn_l":"1201-9712","issn":["1201-9712","1878-3511"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://www.ijidonline.com/article/S120197122032453X/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037498662","display_name":"Zarir Udwadia","orcid":"https://orcid.org/0000-0002-1830-3259","observed_orcids":["https://orcid.org/0000-0002-1830-3259"]},"institutions":[{"id":"https://openalex.org/I2800671109","display_name":"Breach Candy Hospital","ror":"https://ror.org/01nzrqm94","country_code":"IN","type":"healthcare","lineage":["https://openalex.org/I2800671109"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Zarir F. Udwadia","raw_affiliation_strings":["Breach Candy Hospital, Mumbai, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breach Candy Hospital, Mumbai, India","institution_ids":["https://openalex.org/I2800671109"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064278147","display_name":"Pawan Singh","orcid":"https://orcid.org/0000-0002-3212-9875","observed_orcids":["https://orcid.org/0000-0002-3212-9875"]},"institutions":[{"id":"https://openalex.org/I4210131532","display_name":"Glenmark Pharmaceuticals (India)","ror":"https://ror.org/037fhg487","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210131532"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Pawan Singh","raw_affiliation_strings":["Glenmark Pharmaceuticals Limited, Mumbai, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glenmark Pharmaceuticals Limited, Mumbai, India","institution_ids":["https://openalex.org/I4210131532"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070489582","display_name":"Hanmant V. Barkate","orcid":"https://orcid.org/0000-0003-4346-9194","observed_orcids":["https://orcid.org/0000-0003-4346-9194"]},"institutions":[{"id":"https://openalex.org/I4210131532","display_name":"Glenmark Pharmaceuticals (India)","ror":"https://ror.org/037fhg487","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210131532"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Hanmant Barkate","raw_affiliation_strings":["Glenmark Pharmaceuticals Limited, Mumbai, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glenmark Pharmaceuticals Limited, Mumbai, India","institution_ids":["https://openalex.org/I4210131532"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103215900","display_name":"Saiprasad Patil","orcid":"https://orcid.org/0000-0002-4937-3188","observed_orcids":["https://orcid.org/0000-0002-4937-3188"]},"institutions":[{"id":"https://openalex.org/I4210131532","display_name":"Glenmark Pharmaceuticals (India)","ror":"https://ror.org/037fhg487","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210131532"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Saiprasad Patil","raw_affiliation_strings":["Glenmark Pharmaceuticals Limited, Mumbai, India"],"raw_orcid":"https://orcid.org/0000-0002-4937-3188","affiliations":[{"raw_affiliation_string":"Glenmark Pharmaceuticals Limited, Mumbai, India","institution_ids":["https://openalex.org/I4210131532"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017570777","display_name":"Shabbir Rangwala","orcid":"https://orcid.org/0000-0002-7563-2593","observed_orcids":["https://orcid.org/0000-0002-7563-2593"]},"institutions":[{"id":"https://openalex.org/I4210131532","display_name":"Glenmark Pharmaceuticals (India)","ror":"https://ror.org/037fhg487","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210131532"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Shabbir Rangwala","raw_affiliation_strings":["Glenmark Pharmaceuticals Limited, Mumbai, India"],"raw_orcid":"https://orcid.org/0000-0002-7563-2593","affiliations":[{"raw_affiliation_string":"Glenmark Pharmaceuticals Limited, Mumbai, India","institution_ids":["https://openalex.org/I4210131532"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065469040","display_name":"Amol Pendse","orcid":"https://orcid.org/0000-0001-6333-7098","observed_orcids":["https://orcid.org/0000-0001-6333-7098"]},"institutions":[{"id":"https://openalex.org/I4210131532","display_name":"Glenmark Pharmaceuticals (India)","ror":"https://ror.org/037fhg487","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210131532"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Amol Pendse","raw_affiliation_strings":["Glenmark Pharmaceuticals Limited, Mumbai, India"],"raw_orcid":"https://orcid.org/0000-0001-6333-7098","affiliations":[{"raw_affiliation_string":"Glenmark Pharmaceuticals Limited, Mumbai, India","institution_ids":["https://openalex.org/I4210131532"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062095052","display_name":"Jatin Kadam","orcid":"https://orcid.org/0000-0002-1391-988X","observed_orcids":["https://orcid.org/0000-0002-1391-988X"]},"institutions":[{"id":"https://openalex.org/I4210131532","display_name":"Glenmark Pharmaceuticals (India)","ror":"https://ror.org/037fhg487","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210131532"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Jatin Kadam","raw_affiliation_strings":["Glenmark Pharmaceuticals Limited, Mumbai, India"],"raw_orcid":"https://orcid.org/0000-0002-1391-988X","affiliations":[{"raw_affiliation_string":"Glenmark Pharmaceuticals Limited, Mumbai, India","institution_ids":["https://openalex.org/I4210131532"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104235298","display_name":"Wen Wu","orcid":"https://orcid.org/0009-0000-4830-9419","observed_orcids":["https://orcid.org/0009-0000-4830-9419"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wen Wu","raw_affiliation_strings":["Glenmark Pharmaceuticals Ltd, Waterford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glenmark Pharmaceuticals Ltd, Waterford, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043800959","display_name":"Cynthia F. Caracta","orcid":"https://orcid.org/0000-0002-8841-873X","observed_orcids":["https://orcid.org/0000-0002-8841-873X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cynthia F. Caracta","raw_affiliation_strings":["Glenmark Pharmaceuticals, Inc., Mahwah, NJ, USA"],"raw_orcid":"https://orcid.org/0000-0002-8841-873X","affiliations":[{"raw_affiliation_string":"Glenmark Pharmaceuticals, Inc., Mahwah, NJ, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5008131846","display_name":"Monika Tandon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131532","display_name":"Glenmark Pharmaceuticals (India)","ror":"https://ror.org/037fhg487","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210131532"]}],"countries":["IN"],"is_corresponding":true,"raw_author_name":"Monika Tandon","raw_affiliation_strings":["Glenmark Pharmaceuticals Limited, Mumbai, India. Electronic address: Monika.Tandon@glenmarkpharma.com","Glenmark Pharmaceuticals Limited, Mumbai, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glenmark Pharmaceuticals Limited, Mumbai, India. Electronic address: Monika.Tandon@glenmarkpharma.com","institution_ids":["https://openalex.org/I4210131532"]},{"raw_affiliation_string":"Glenmark Pharmaceuticals Limited, Mumbai, India","institution_ids":["https://openalex.org/I4210131532"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5008131846"],"corresponding_institution_ids":["https://openalex.org/I4210131532"],"apc_list":{"value":1750,"currency":"USD","value_usd":1750},"apc_paid":{"value":1750,"currency":"USD","value_usd":1750},"fwci":8.2821,"has_fulltext":true,"cited_by_count":293,"citation_normalized_percentile":{"value":0.9816006,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"103","issue":null,"first_page":"62","last_page":"71"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10041","display_name":"COVID-19 Clinical Research Studies","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10041","display_name":"COVID-19 Clinical Research Studies","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.006800000090152025,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11243","display_name":"Respiratory viral infections research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/favipiravir","display_name":"favipiravir","score":1.0},{"id":"https://openalex.org/keywords/covid-19","display_name":"COVID-19 pandemic","score":0.9919999837875366},{"id":"https://openalex.org/keywords/sars-cov-2","display_name":"SARS-CoV-2","score":0.9800000190734863},{"id":"https://openalex.org/keywords/rna-dependent-rna-polymerase-inhibitors","display_name":"RNA-dependent RNA polymerase inhibitors","score":0.9789999723434448},{"id":"https://openalex.org/keywords/antiviral-therapy","display_name":"antiviral therapy","score":0.8809999823570251},{"id":"https://openalex.org/keywords/viral-shedding","display_name":"viral shedding","score":0.8140000104904175},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6840000152587891},{"id":"https://openalex.org/keywords/mild-to-moderate-covid-19","display_name":"mild to moderate COVID-19","score":0.902999997138977}],"concepts":[{"id":"https://openalex.org/C2779772310","wikidata":"https://www.wikidata.org/wiki/Q16934561","display_name":"Favipiravir","level":5,"score":0.9641343951225281},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8441088199615479},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.7328592538833618},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.6552056670188904},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6237287521362305},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5596736073493958},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5468924641609192},{"id":"https://openalex.org/C2777910003","wikidata":"https://www.wikidata.org/wiki/Q1707292","display_name":"Asymptomatic","level":2,"score":0.5303595662117004},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.32160502672195435},{"id":"https://openalex.org/C3008058167","wikidata":"https://www.wikidata.org/wiki/Q84263196","display_name":"Coronavirus disease 2019 (COVID-19)","level":4,"score":0.2974488139152527},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.20317018032073975},{"id":"https://openalex.org/C524204448","wikidata":"https://www.wikidata.org/wiki/Q788926","display_name":"Infectious disease (medical specialty)","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000086402","descriptor_name":"SARS-CoV-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000093485","descriptor_name":"COVID-19 Drug Treatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000577","descriptor_name":"Amides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000577","descriptor_name":"Amides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012324","descriptor_name":"RNA-Dependent RNA Polymerase","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1016/j.ijid.2020.11.142","doi":"https://doi.org/10.1016/j.ijid.2020.11.142","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ijid.2020.11.142","pdf_url":"http://www.ijidonline.com/article/S120197122032453X/pdf","source":{"id":"https://openalex.org/S35071406","display_name":"International Journal of Infectious Diseases","issn_l":"1201-9712","issn":["1201-9712","1878-3511"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Infectious Diseases","raw_type":"journal-article"},{"id":"pmid:33212256","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33212256","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:pubmedcentral.nih.gov:7668212","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7668212/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int J Infect Dis","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:4e4066fdaf884deba2ec80352ad2f675","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/4e4066fdaf884deba2ec80352ad2f675","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"International Journal of Infectious Diseases, Vol 103, Iss , Pp 62-71 (2021)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1016/j.ijid.2020.11.142","doi":"https://doi.org/10.1016/j.ijid.2020.11.142","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ijid.2020.11.142","pdf_url":"http://www.ijidonline.com/article/S120197122032453X/pdf","source":{"id":"https://openalex.org/S35071406","display_name":"International Journal of Infectious Diseases","issn_l":"1201-9712","issn":["1201-9712","1878-3511"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Infectious Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320319417","display_name":"Glenmark Pharmaceuticals","ror":"https://ror.org/037fhg487"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3098266159.pdf","grobid_xml":"https://content.openalex.org/works/W3098266159.grobid-xml"},"referenced_works_count":28,"referenced_works":["https://openalex.org/W2060514161","https://openalex.org/W2417105226","https://openalex.org/W2596216730","https://openalex.org/W2739679816","https://openalex.org/W2791347300","https://openalex.org/W3004280078","https://openalex.org/W3008028633","https://openalex.org/W3009828946","https://openalex.org/W3012455685","https://openalex.org/W3013558861","https://openalex.org/W3016084006","https://openalex.org/W3016173697","https://openalex.org/W3023489051","https://openalex.org/W3024220416","https://openalex.org/W3025172442","https://openalex.org/W3025444323","https://openalex.org/W3025770784","https://openalex.org/W3032350507","https://openalex.org/W3034761381","https://openalex.org/W3048223030","https://openalex.org/W3080718665","https://openalex.org/W3081640332","https://openalex.org/W3087465356","https://openalex.org/W3093988179","https://openalex.org/W3110153761","https://openalex.org/W3197627421","https://openalex.org/W6774602036","https://openalex.org/W6775471753"],"related_works":["https://openalex.org/W3102015759","https://openalex.org/W4294840172","https://openalex.org/W4205602210","https://openalex.org/W4226074581","https://openalex.org/W3195526405","https://openalex.org/W3158369907","https://openalex.org/W4283692758","https://openalex.org/W3152631365","https://openalex.org/W4392135173","https://openalex.org/W3087465356"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"assess":[2],"the":[3,70,107,193,201],"efficacy":[4],"and":[5,34,50,133,162,173],"safety":[6],"of":[7,72,109,171,175,189,200],"favipiravir":[8,44,95,161,172,212],"in":[9,169,206,216],"adults":[10,27],"with":[11,30],"mild-to-moderate":[12,35,217],"coronavirus":[13],"disease":[14],"2019":[15],"(COVID-19).":[16],"METHODS:":[17],"In":[18],"this":[19],"randomized,":[20],"open-label,":[21],"parallel-arm,":[22],"multicenter,":[23],"phase":[24],"3":[25,140,144],"trial,":[26],"(18-75":[28],"years)":[29],"RT-PCR":[31,202],"confirmed":[32],"COVID-19":[33],"symptoms":[36],"(including":[37],"asymptomatic)":[38],"were":[39,92,167],"randomized":[40,93],"1:1":[41],"to":[42,69,76,86,94,106,136,183,208],"oral":[43],"(day":[45],"1:":[46],"1800":[47],"mg":[48,54],"BID":[49],"days":[51,114,123,141,150],"2-14:":[52],"800":[53],"BID)":[55],"plus":[56],"standard":[57],"supportive":[58,61],"care":[59,62],"versus":[60,121,148],"alone.":[63],"The":[64,187],"primary":[65,194],"endpoint":[66,195],"was":[67,79,112,139,196],"time":[68,75,105,135,207],"cessation":[71,108],"viral":[73,110],"shedding;":[74],"clinical":[77,137,209],"cure":[78,138,210],"also":[80],"measured.":[81],"RESULTS:":[82],"From":[83],"May":[84],"14":[85],"July":[87],"3,":[88],"2020,":[89],"150":[90],"patients":[91],"(n":[96,101],"=":[97,102,131,158],"75)":[98],"or":[99],"control":[100,176,179],"75).":[103],"Median":[104],"shedding":[111],"5":[113,126,149],"(95%":[115,124,142,151],"CI:":[116,125,143,152],"4":[117,146,153],"days,":[118,127,145,154],"7":[119,122],"days)":[120,147],"8":[128],"days),":[129,156],"P":[130,157],"0.129,":[132],"median":[134],"6":[155],"0.030,":[159],"for":[160],"control,":[163],"respectively.":[164],"Adverse":[165],"events":[166],"observed":[168],"36%":[170],"8%":[174],"patients.":[177],"One":[178],"patient":[180],"died":[181],"due":[182],"worsening":[184],"disease.":[185],"CONCLUSION:":[186],"lack":[188],"statistical":[190],"significance":[191],"on":[192],"confounded":[197],"by":[198],"limitations":[199],"assay.":[203],"Significant":[204],"improvement":[205],"suggests":[211],"may":[213],"be":[214],"beneficial":[215],"COVID-19.":[218]},"counts_by_year":[{"year":2026,"cited_by_count":14},{"year":2025,"cited_by_count":17},{"year":2024,"cited_by_count":34},{"year":2023,"cited_by_count":40},{"year":2022,"cited_by_count":99},{"year":2021,"cited_by_count":84},{"year":2020,"cited_by_count":4},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2020-11-23T00:00:00"}